Genmab B.v.

Genmab Holding B.v.

Genmab A+s

Frank Beurskens

Paul Parren

Janine Schuurman

Aran Frank Labrijn

Simone Oostindie

Rob N De Jong

Esther Breij

Margaret A Lindorfer

Marije Overdijk

Tuna Mutis

Hilma Van Der Horst

Martine E D Chamuleau

Edward Norbert Van Den Brink

Ronald P Taylor

Andreas Hollenstein

Jan Van De Winkel

Tom Vink

Patrick Van Berkel

Willem Karel Bleeker

Kristin Strumane

Sandra Verploegen

Bart-Jan De Kreuk

Arjen Vlug

Annieck M Diks

Ronald Taylor

Jan GJ Van De Winkel

CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of use thereof

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

Antibody variant combinations and uses thereof

The present invention relates to anti-CD37antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG, for use as a medicament in combination with anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution in the Fc-region of a human IgG. The invention also relates to a novel composition of anti-CD37 antibodies having an Fc-Fc 5 interaction enhancing substitution and anti-CD20 antibodies having an Fc-Fc interaction enhancing substitution. In particular, the invention relates to compositions wherein the anti-CD37 antibody binds human CD37 and the anti-CD20 antibody binds human CD20. The invention also relates to compositions where the composition is a pharmaceutical composition and the use of such compositions in treatment of cancer and other diseases.

Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

Polypeptide variants and uses thereof

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

Antibody variants and uses thereof

The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

Dimeric protein with triple mutations

The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

Recombinant IgG4 monovalent antibodies

The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.

Recombinant monovalent antibodies and methods for production thereof

Growing community of inventors

Utrecht, Netherlands

Frank Beurskens